• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-10-07

  Silasi et al. report that human chorionic gonadotropin suppresses CXCL10 in decidual stromal cells by promoting EZH2-associated H3K27me3 at a defined CXCL10 promoter region. The study links a placental endocrine signal to chromatin regulation and reduced CD8-cell recruitment, while also defining important boundaries for interpreting the findings outside human decidual biology.

• GSK126 and EZH2: Research Context and Evidence

  2026-10-07

  GSK126 is a research tool for examining EZH2–PRC2 chromatin regulation. Evidence from astrocyte HIV-latency research supports a role for H3K27me3 in Tat-associated latency, while oncology applications remain broader supplier-described contexts requiring independent primary studies.

• GSK126 and EZH2: Evidence Across Cancer and Pain

  2026-10-06

  GSK126 is a research compound used to interrogate EZH2 and PRC2-dependent epigenetic regulation. This overview compares vendor-described oncology applications with peer-reviewed evidence linking EZH2 to microglial autophagy and neuropathic pain, while emphasizing provenance, translational limits, and the distinction between EZH2 biology and evidence specifically attributable to GSK126.

• Minocycline HCl in EV Research: An Evidence Map

  2026-10-06

  Minocycline HCl is examined here as a mechanistic comparator for scalable extracellular-vesicle research, not simply as an antibacterial or neuroprotective reagent. This evidence-focused analysis connects minocycline hydrochloride biology with the 2025 EPSC-derived MSC-EV platform while defining what the study does—and does not—demonstrate.

• RGFP966 and HO-1: Interpreting Enzyme Activity

  2026-10-05

  RGFP966 offers a pharmacological lens for examining HDAC3-linked regulation, while activity-based HO-1 imaging reveals why expression data alone can be misleading. This article connects those concepts without treating a mechanistic hypothesis as a reported result.

• Resveratrol, SIRT1, and the Next Neuroprotection Frontier

  2026-10-05

  Resveratrol is emerging as a useful mechanistic probe for connecting SIRT1 activity with mitochondrial biogenesis, apoptosis, and neuronal resilience. New findings in prion-peptide-challenged N2a cells clarify the biology while also defining the evidence gaps that translational researchers must address before treating SIRT1 activation as a therapeutic strategy.

• Entinostat and HDAC Signaling in Regeneration Research

  2026-10-04

  Entinostat, also known as MS-275 or SNDX-275, is a class I HDAC inhibitor studied in oncology and developmental biology. The strongest supplied evidence comes from an axolotl study linking nerve-dependent HDAC1 expression with blastema formation and limb regeneration. Those findings support mechanistic research questions, but they do not establish cancer efficacy or direct clinical relevance.

• Nerve-Dependent HDAC1 Controls Axolotl Limb Regeneration

  2026-10-03

  Wang and colleagues linked nerve signaling to HDAC1 expression in the wound epidermis and to blastema formation during axolotl limb regeneration. Their convergent pharmacological, denervation, expression, and nerve-factor experiments support a model in which HDAC1 acts as an important epigenetic component of nerve-dependent regenerative competence, while leaving the precise downstream gene network unresolved.

• Mdivi-1: Selective DRP1 Inhibitor Workflows

  2026-10-02

  Mdivi-1 enables controlled testing of mitochondrial fission, apoptosis, and tissue-protection mechanisms across cell and animal models. This guide translates a chronic intermittent hypoxia co-metabolomics study into practical assay design, dosing, controls, and troubleshooting strategies.

• AZD8055 Practical mTOR Inhibitor Workflow

  2026-10-01

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cancer-cell proliferation, and metabolic responses. This guide covers formulation, assay controls, and interpretation while defining limits: it is a preclinical research tool, not a substitute for clinical efficacy evidence or a suitable choice for aqueous formulations.

• RGFP966 Workflows for HO-1 Activity Studies

  2026-10-01

  Use RGFP966 as a mechanistic perturbation alongside an activity-sensitive HO-1 fluorescence workflow, rather than relying on expression measurements alone. This approach connects epigenetic intervention with live-cell localization, macrophage biology, and serum-compatible assay development.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-09-30

  This review synthesizes two decades of clinical experience with toremifene, showing that it is an effective endocrine option for postmenopausal patients with hormone-sensitive breast cancer, with efficacy broadly comparable to tamoxifen in the reviewed evidence. Its distinct metabolic profile and tissue-selective estrogenic effects provide a rationale for individualized use, although the review does not establish a universal safety advantage.

• DiscoveryProbe Metabolism-related Compound Library

  2026-09-30

  Translate metabolomic observations into tractable enzyme, cell, and pathway screens with a curated 493-compound collection. This workflow shows how to connect lipid remodeling and stress-response findings from burn research with reproducible metabolic perturbation assays, while controlling for potency, cytotoxicity, and DMSO effects.

• Triacetin: From Digestion to Research Design

  2026-09-29

  Triacetin, or glyceryl triacetate, is more than a synthetic triglyceride: its rapid conversion to acetate and glycerol changes how metabolic, oncology, and ocular assays should be designed. This evidence-led guide connects biochemical fate with exposure controls, mechanistic interpretation, and reproducible workflow decisions.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-09-29

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and resistance to dopamine agonists. Its combination of CRISPR screening, proteomics, ubiquitination analysis, and drug screening positions TRIM21 suppression as a testable strategy while highlighting the importance of ERK1/2 feedback.

8684 records 1/579 page Next 12345 下5页 Last page